Teva is quick out of the gate
The pharmaceutical company is preparing for an earlier-than-expected launch of a new generic contraceptive.
Of these, Gianvi is the biggie -- at least for now.
The drug is a generic version of Bayer’s (BAYRY) oral contraceptive Yaz. Sales of Yaz came to $780 million in 2009. The contraceptive has been especially popular among younger women, since taking it produces less water retention than some other contraceptives and works to reduce acne.
But sales of Yaz have dropped recently to an annual rate of about $600 million as Bayer has cut back on advertising and promotion. (Bayer’s newest contraceptive, Natazia, was approved for sale in May.)
Teva’s launch of Gianvi comes about 13 months ahead of schedule (Wall Street was expecting a 2011 launch), and because Teva is first to file for generic rights, the company will get 180 days of marketing exclusivity.
Gianvi will add about 10 cents a share to annual earnings at Teva and with some of that already in the price, I’d estimate, I don’t see any reason to raise my target price of $66 a share by October 2010 (It traded above $53 late Thursday).
This kind of quick-to-market approach represented by the launch of Gianvi should remind us why Teva is the generic stock in Jubak’s Picks. (For more on generics and the increasing importance of emerging economies to drug makers, see this post).
At the time of this writing, Jim Jubak owned shares of Teva Pharmaceutical Industries in his personal portfolio.
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
After enjoying a smooth rise in stock prices since May, investors are about to be hit with another bout of volatility.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.